Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Benzaquen

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|February 6, 2025
PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance databaseAlexandre O Gérard, Diane Merino, Jonathan Benzaquen, et al.
Journal of Visualized Experiments : Jove|September 25, 2023
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung CancerChristophe Bontoux, Virginie Lespinet-Fabre, Olivier Bordone, et al.
The Lancet. Respiratory Medicine|July 11, 2020
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort studyCharles-Hugo Marquette, Jacques Boutros, Jonathan Benzaquen, et al.
Cancers|October 16, 2024
Impact of the Lung Microbiota on Development and Progression of Lung CancerAmine Belaid, Barnabé Roméo, Guylène Rignol, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2022
Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancerMarius Ilié, Mélanie Beaulande, Elodie Long-Mira, et al.
Journal of Translational Medicine|February 19, 2020
Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institutionSimon Heeke, Véronique Hofman, Marius Ilié, et al.
Bulletin Du Cancer|July 11, 2020
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumabLinda Bouhlel, Jérôme Doyen, Emmanuel Chamorey, et al.
Cancers|March 22, 2018
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 PatientsSimon Heeke, Véronique Hofman, Elodie Long-Mira, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2020
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France)Véronique Hofman, Jonathan Benzaquen, Simon Heeke, et al.
Theranostics|October 12, 2020
P2RX7B is a new theranostic marker for lung adenocarcinoma patientsJonathan Benzaquen, Serena Janho Dit Hreich, Simon Heeke, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|February 6, 2025
PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance databaseAlexandre O Gérard, Diane Merino, Jonathan Benzaquen, et al.
Journal of Visualized Experiments : Jove|September 25, 2023
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung CancerChristophe Bontoux, Virginie Lespinet-Fabre, Olivier Bordone, et al.
The Lancet. Respiratory Medicine|July 11, 2020
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort studyCharles-Hugo Marquette, Jacques Boutros, Jonathan Benzaquen, et al.
Cancers|October 16, 2024
Impact of the Lung Microbiota on Development and Progression of Lung CancerAmine Belaid, Barnabé Roméo, Guylène Rignol, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2022
Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancerMarius Ilié, Mélanie Beaulande, Elodie Long-Mira, et al.
Journal of Translational Medicine|February 19, 2020
Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institutionSimon Heeke, Véronique Hofman, Marius Ilié, et al.
Bulletin Du Cancer|July 11, 2020
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumabLinda Bouhlel, Jérôme Doyen, Emmanuel Chamorey, et al.
Cancers|March 22, 2018
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 PatientsSimon Heeke, Véronique Hofman, Elodie Long-Mira, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2020
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France)Véronique Hofman, Jonathan Benzaquen, Simon Heeke, et al.
Theranostics|October 12, 2020
P2RX7B is a new theranostic marker for lung adenocarcinoma patientsJonathan Benzaquen, Serena Janho Dit Hreich, Simon Heeke, et al.
Pageof 6